Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutations predict response to EGFR inhibitors.

Current opinion in pharmacology - 1 Aug 2008

Raponi Mitch, Winkler Hans, Dracopoli Nicholas C

Abstract excerpt

Five antiepidermal growth factor receptor therapies have been approved for the treatment of solid tumors. However, response rates are relatively low. Several biomarkers that enrich for patients with tumors most likely to respond to these therapeutic agents have been identified. Mutations in the intermediate signal transduction pathway member KRAS also selects patients with tumors depending on signaling through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Disease Progression
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival

Source

Identifiers

PMID: 18619559
DOI: 10.1016/j.coph.2008.06.006

Genes

KRAS
EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations predict response to EGFR inhibitors.PMID 18619559Read ↗

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.Semantic proximity Read ↗

KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.Semantic proximity Read ↗

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Semantic proximity Read ↗

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

Clinical significance of the KRAS mutation.Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

EGFR and KRAS in colorectal cancer.Semantic proximity Read ↗

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.